IRBM

𝗚𝗿𝗲𝗮𝘁 𝗶𝗱𝗲𝗮𝘀 𝗶𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗳𝘁𝗲𝗻 𝗯𝗲𝗴𝗶𝗻 𝘄𝗶𝘁𝗵 𝗴𝗿𝗲𝗮𝘁 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀. 💡🔗 That’s why we’re excited to attend 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 2024 in Stockholm, where meaningful discussions can spark new partnerships and innovative solutions in drug discovery. From November 4-6, our team will be at 𝗕𝗼𝗼𝘁𝗵 𝟖𝟎 ready to talk about our internal oncology pipeline as well as how our collaborative approach can help move your research forward. Whether it’s small molecules, peptides, antibodies or cutting edge scientific approaches that help advance therapeutics to patients, we’d love to connect. Stop by to meet Michele Luche and Ali Hoseini, PhD, MBA—we look forward to inspiring conversations and exploring new opportunities together! #BIOEurope #LifeSciences #DrugDiscovery #IRBM

Meaningful progress happens when 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗲𝘀 𝗮𝗻𝗱 𝗽𝘂𝗯𝗹𝗶𝗰 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 𝘂𝗻𝗶𝘁𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗼𝗻 𝗴𝗼𝗼𝗱. Yesterday, IRBM had the honor of joining the 𝟐𝟎𝟐𝟒 𝗚𝟕 𝗠𝗶𝗻𝗶𝘀𝘁𝗲𝗿𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗠𝗲𝗲𝘁𝗶𝗻𝗴, where our CEO, Matteo Liguori, represented us in discussing how international public-private partnerships can accelerate drug and vaccine development to address global health challenges. Initiatives like those led by Gavi, the Vaccine Alliance, under the leadership of 𝘑𝘰𝘴𝘦 𝘔𝘢𝘯𝘶𝘦𝘭 𝘉𝘢𝘳𝘳𝘰𝘴𝘰, are driving critical change by promoting fairer access to healthcare and fostering stronger scientific foundations. Through these collaborative networks, we’re not only building a more 𝗲𝗾𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗹𝘁𝗵 𝘀𝘆𝘀𝘁𝗲𝗺 but also enhancing our ability to 𝗰𝗼𝗻𝗳𝗿𝗼𝗻𝘁 𝗳𝘂𝘁𝘂𝗿𝗲 𝗵𝗲𝗮𝗹𝘁𝗵 𝗲𝗺𝗲𝗿𝗴𝗲𝗻𝗰𝗶𝗲𝘀 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆. A special thank you to Minister Antonio Tajani and the G7 organizers for driving this important dialogue. It’s inspiring to see shared goals leading to more equitable health solutions and deeper connections with scientific communities worldwide—especially in Africa, where invaluable expertise strengthens the fight against emerging diseases. We are proud to contribute to this global effort for tangible, life-saving change —and we invite supporters everywhere to join the cause! #G7Italia2024 #G7 #IRBM #GlobalHealth 

Mucopolysaccharidosis type IIIA (MPS IIIA) is a rare and progressive lysosomal storage disorder caused by mutations in the 𝗵𝗲𝗽𝗮𝗿𝗮𝗻-𝗡-𝘀𝘂𝗹𝗽𝗵𝗮𝘁𝗮𝘀𝗲 enzyme, resulting in the accumulation of heparan sulfate—a toxic process that damages the central nervous system. 🧠 In our latest publication, we proudly introduce a 𝗻𝗼𝘃𝗲𝗹 𝗟𝗖-𝗠𝗦/𝗠𝗦 𝗮𝘀𝘀𝗮𝘆 designed to measure heparan-N-sulphatase activity in pediatric cerebrospinal fluid. By providing precise evaluation of treatments aimed at restoring enzyme function, this assay offers powerful support in the development of new, targeted therapies for MPS IIIA patients. Congratulations to Roberto Speziale, Laura Orsatti, Savina Malancona, 𝘋𝘢𝘯𝘪𝘭𝘰 𝘍𝘢𝘣𝘣𝘳𝘪𝘯𝘪, and the rest of the talented team for your exceptional work! At IRBM, our focus on advancing drug discovery for rare diseases continues. #MPSIIIA #RareDiseases #DrugDiscovery #IRBM

The landscape of cancer treatment is ever-evolving with continuous advancements in drug modalities such as peptides, radiotheranostics, small molecules, and antibody-drug conjugates. At IRBM, our scientists are at the forefront of innovation in these transformative approaches. With expertise in various oncology programs—including the approved ovarian cancer therapy ZEJULA®—and ongoing internal projects, including our own allosteric SHP2 inhibitor for brain tumors and metastases, as well as our CRLF2-targeting ADC, we help partners move swiftly from concept to clinical readiness in oncology drug discovery. Join us at the 𝟑𝟔𝘁𝗵 𝗘𝗢𝗥𝗧𝗖-𝗡𝗖𝗜-𝗔𝗔𝗖𝗥 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 in Barcelona, October 23-25, where you can connect with Alessandro Carugo and Ali Hoseini, PhD, MBA to explore how our capabilities can accelerate your oncology research program and how our internal assets can enhance your therapeutic pipeline. EORTC - European Organisation for Research and Treatment of Cancer National Cancer Institute (NCI) American Association for Cancer Research #ENA2024 #CancerResearch #Oncology #DrugDiscovery #IRBM

⚠️ A recent, 𝗴𝗹𝗼𝗯𝗮𝗹 study featured in Nature Magazine found that nearly 𝟓𝟎% 𝗼𝗳 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗹𝗲𝗮𝘃𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝘄𝗶𝘁𝗵𝗶𝗻 𝟏𝟎 𝘆𝗲𝗮𝗿𝘀. While gender gaps are narrowing, women still leave at significantly higher rates than men, particularly in fields like biochemistry, genetics, and molecular biology, which are crucial to drug discovery. The research pointed to numerous studies showing that workplace culture—not just work-life balance—often drives women away from science, which underscores the need for more supportive and inclusive environments. At IRBM, we believe science can flourish anywhere—not just within academic walls—and we are proud to be part of that reality. 🧪 With over 𝟔𝟎% 𝗼𝗳 𝗼𝘂𝗿 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 and 60% of our management team being 𝗯𝗿𝗶𝗹𝗹𝗶𝗮𝗻𝘁 𝘄𝗼𝗺𝗲𝗻, our researchers have authored 𝟖𝟎𝟎+ 𝗽𝗲𝗲𝗿-𝗿𝗲𝘃𝗶𝗲𝘄𝗲𝗱 𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀. This demonstrates that the pursuit of scientific excellence can thrive throughout one's career, where experienced mentors emerge and inspire the next generation. If you're looking for a place where your discoveries can thrive, remember that science has many homes—you just have to find the one where your passion can grow. 🌱 → Check out our 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗼𝗽𝗲𝗻𝗶𝗻𝗴𝘀 here: https://bit.ly/4dUFOIF #IRBM #Scienceforlife #womeninstem #drugdiscovery

Analytical chromatography is fundamental for quality control ensuring the high purity of screening compounds. At IRBM, we prioritize sample purity and structural integrity needed to advance drug discovery programs with the highest chances of success. Our 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗽𝘂𝗿𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗲𝗮𝗺 supports the whole process with both automated and tailored manual approaches to ensure every compound and key intermediate meet rigorous purity standards. Additionally, the team performs comprehensive quality analysis of our compound collection, assessing stability, consistency, and overall integrity across batches. Supported by an impressive suite of instrumentation—from UPLC/ELSD/MS and NMR to advanced chemoinformatics—we implement rigorous methodologies to deliver optimized compound sets. This ensures our partners are well-equipped for the next stage of development. Join us at the 19th 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗣𝗿𝗲𝗽𝗮𝗿𝗮𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗖𝗵𝗿𝗼𝗺𝗮𝘁𝗼𝗴𝗿𝗮𝗽𝗵𝘆 (SPICA) in Milan from October 15-18, where our expert Costanza Iaccarino, will be available to discuss how our tailored chromatography solutions and advanced quality system accelerate hit finding and optimize drug discovery outcomes. We look forward to connecting with you at SPICA! #SPICA2024 #Chromatography #DrugDiscovery #IRBM

For many young scientists, the transition from the lab to the business world can feel like stepping into uncharted territory. Where do you even begin? 🤔 Last week, Michael Ziebell, Ph.D. from our Business Development team, shared his journey at the Underrepresented Early Career Scientists (UECS) Career Development Panel at the Dana-Farber Cancer Institute, offering valuable advice to those facing this very question. In a candid conversation, Michael tackled the realities of this shift—how different the two roles really are, the challenges of learning the commercial side, and the skills that translate best when making the leap. His insights were a guiding light for scientists exploring opportunities beyond the bench.   At IRBM we’ve seen firsthand how a scientific background can be a real advantage in business roles within a biotech company. We’d love to hear from scientists who've already taken that step. 💡   💬 If this sounds like you, let’s talk!   Explore the possibilities: https://lnkd.in/dYKry9id   A special thank you to the Dana Farber UECS Organizing Committee for hosting this event!     #CareerDevelopment #Recruitment #IRBM

We're #hiring a new Jr Research Scientist - Peptide Chemistry in Pomezia, Latium. Apply today or share this post with your network.

🔬 Specialized assays have the 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗼𝗿 𝗯𝗿𝗲𝗮𝗸 𝗮 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗽𝗿𝗼𝗴𝗿𝗮𝗺, serving as the critical foundation for generating reliable data that drives target validation, hit identification, and lead optimization. Recognizing the pivotal role of target-specific assays and customized screening strategies, we’re proud to spotlight the remarkable work of Mariachiara Micaelli, who will be presenting her poster at 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝟐𝟎𝟐𝟒: “𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘣𝘪𝘰𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘣𝘪𝘰𝘱𝘩𝘺𝘴𝘪𝘤𝘢𝘭 𝘢𝘴𝘴𝘢𝘺𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘦𝘱𝘵𝘪𝘥𝘦𝘴 𝘵𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘔𝘓𝘏1-𝘔𝘚𝘏3 𝘱𝘳𝘰𝘵𝘦𝘪𝘯-𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘪𝘯𝘵𝘦𝘳𝘢𝘤𝘵𝘪𝘰𝘯.” The poster will provide details of an advanced peptide program targeting two critical proteins involved in the 𝗗𝗡𝗔 𝗠𝗶𝘀𝗺𝗮𝘁𝗰𝗵 𝗥𝗲𝗽𝗮𝗶𝗿 𝗽𝗮𝘁𝗵𝘄𝗮𝘆. These proteins play a vital role in somatic CAG triplet repeat expansion, which is implicated in Huntington’s disease. What makes this research particularly compelling is the focus on the development of these precise assays that guide the Structure-Activity Relationship (SAR), leading to the synthesis of increasingly potent peptides. We invite you to visit us at: 📍 𝗣𝗼𝘀𝘁𝗲𝗿 𝟔𝟔 📆 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟐𝗻𝗱, 17:00-17:30 (Networking session) 📆 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟑𝗿𝗱, 13:00-13:30 (Refreshment break) See you in London! #DrugDiscovery2024 #HuntingtonsDisease #PeptideTherapeutics #IRBM

Managing a highly curated small molecule library isn’t just science, it’s an art — one that’s powered by automation, innovation, and attention to detail. 🎨🔬 At the XXVIII EFMC International Symposium on Medicinal Chemistry, Laura Mangiardi, Principal Research Scientist at IRBM, shared insights into our fully automated platform for compound collection management for High Throughput Screening. This platform addresses the growing complexity and size of compound libraries, which have expanded significantly with advancements in chemistry and medicinal design, underscoring the need for more efficient and scalable end-to-end management solutions in drug discovery. 💡Don’t miss this edition of “𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗕𝗶𝘁𝗲𝘀” by IRBM, and mark your calendars for the upcoming SLAS (Society for Laboratory Automation and Screening) 2024 Sample Management Symposium to learn more about how we’re speeding up the discovery of new therapeutics by adding efficiency, accuracy, and scalability to every step of the process. #EFMC2024 #DrugDiscovery #MedicinalChemistry #IRBM